Trial reportBiological psychiatry2019
RETRACTED: Effects of L-DOPA Monotherapy on Psychomotor Speed and [
Trial report in Biological psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The Frail Depressed Patient: A Narrative Review on Treatment Challenges.Clinical interventions in aging · 2022Pooled it
- Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.Molecular psychiatry · 2022Trial
- Frailty and Depression in Late Life: A High-Risk Comorbidity With Distinctive Clinical Presentation and Poor Antidepressant Response.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Trial
- Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.Brain : a journal of neurology · 2026Review
- [Late-life depression and frailty-Epidemiological, clinical and neurobiological associations].Der Nervenarzt · 2023Review
- Increased Inflammation and Treatment of Depression: From Resistance to Reuse, Repurposing, and Redesign.Advances in neurobiology · 2023Article
- Reward System Dysfunction and the Motoric-Cognitive Risk Syndrome in Older Persons.Biomedicines · 2022Article
- Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?Frontiers in pharmacology · 2022Review
- Evaluating depression- and anxiety-like behaviors in non-human primates.Frontiers in behavioral neuroscience · 2022Review
- Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.Current topics in behavioral neurosciences · 2022Review
- Influences of dopaminergic system dysfunction on late-life depression.Molecular psychiatry · 2022Review
- Frailty Worsens Antidepressant Treatment Outcomes in Late Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021Article
- Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications.Pharmacological reviews · 2021Review
- Association between neuromelanin-sensitive MRI signal and psychomotor slowing in late-life depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study.Journal of affective disorders · 2020Article
- Resting state connectivity within the basal ganglia and gait speed in older adults with cerebral small vessel disease and locomotor risk factors.NeuroImage. Clinical · 2020Article
Corrections and comments
- Retraction · 2023-01-16Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Error in Data · Error in Methods · Falsification/Fabrication of Data · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · · see also: https://www.thetransmitter.org/retraction/flawed-protocol-for-levodopa-clinical-trial-brings-retractions/; bret R Rutherford has ORI finding of misconduct, see: https://ori.hhs.gov/content/case-summary-rutherford-bret;
- Commented on by
- Retracted
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of Biological Psychiatry Editor John H. Krystal, M.D., with agreement from all authors except Chen Chen and Emily Valente. These two co-authors moved and, with no forwarding information that was available or could be found, they were therefore unable to be contacted. The authors have uncovered irregularities and deviations from the approved protocol related to the work reported in this article. Treatment with antidepressant medications within the past 28 days was an exclusion criterion: “Subjects were excluded for… current treatment or treatment within the past 4 weeks with psychotropic or other medications known to affect dopamine.” Individuals taking an ineffective antidepressant medication who otherwise met study criteria were to undergo a study-supervised medication taper to discontinue their medication for the required period prior to study participation. The published article does not describe that a subgroup of participants (15 out of the 47 consented subjects) enrolled in the study while taking an ineffective antidepressant medication. Of this subgroup, 10 individuals were successfully tapered off their medication and were among the 36 subjects contributing data to the analyses described. In addition, the authors have found that 8 participants did not complete the required 28-day washout prior to beginning the study. For these 8 participants, the medication-free period ranged from 1 to 21 days, with a mean of 10.1 days. Separately, an inclusion criterion was that eligible subjects “had Center for Epidemiologic Studies—Depression Rating scale score ≤ 10.” However, the authors have found that 3 ineligible participants were included, each of whom had depressive symptom scores 1 point out of range for eligibility. Lastly, the CONSORT diagram in Figure S1 states that 11 participants were lost to follow-up. However, this is incorrect. Instead, 9 participants were lost to follow up and 2 participants were screen failures. The authors voluntarily informed the Journal of these honest errors upon discovery. Because of the extent of these issues, the editors and authors concluded that the only course of action was to retract this paper. However, the authors are revising the paper, which the Journal will consider further for publication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.